{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:37Z","timestamp":1792813237949,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Angers University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03088-w","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:26:41Z","timestamp":1785742001000},"page":"2309-2319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis"],"prefix":"10.1038","volume":"40","author":[{"given":"Carole","family":"Mosnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Copin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Quintin-Rou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-6584","authenticated-orcid":false,"given":"Eric","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7056-9257","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"M\u00e9rillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertille","family":"Pawlicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0198-8826","authenticated-orcid":false,"given":"Joris","family":"Argentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-3464","authenticated-orcid":false,"given":"L\u00e9a","family":"Sureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Malinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Sevestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Demoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Aub\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Reboux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Farhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Giltat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nunes Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5216","authenticated-orcid":false,"given":"Mathilde","family":"Hunault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Delneste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4678-2138","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Ugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-7287","authenticated-orcid":false,"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-675X","authenticated-orcid":false,"given":"Damien","family":"Luque Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"3088_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"3088_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/ajh.10116","volume":"70","author":"J Thiele","year":"2002","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol. 2002;70:283\u201391.","journal-title":"Am J Hematol"},{"key":"3088_CR3","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"3088_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","volume":"111","author":"BS Wilkins","year":"2008","unstructured":"Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111:60\u201370.","journal-title":"Blood"},{"key":"3088_CR5","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1365-2559.2010.03545.x","volume":"56","author":"M Brousseau","year":"2010","unstructured":"Brousseau M, Parot-Schinkel E, Moles M-P, Boyer F, Hunault M, Rousselet M-C. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology. 2010;56:758\u201367.","journal-title":"Histopathology"},{"key":"3088_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1309\/AJCP2UG9SGGWAHUA","volume":"136","author":"SM Koopmans","year":"2011","unstructured":"Koopmans SM, Bot FJ, Lam KH, van Marion AMW, de Raeve H, Hebeda KM. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia. Am J Clin Pathol. 2011;136:618\u201324.","journal-title":"Am J Clin Pathol"},{"key":"3088_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2011.047811","volume":"97","author":"T Buhr","year":"2012","unstructured":"Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97:360\u20135.","journal-title":"Haematologica"},{"key":"3088_CR8","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"117","author":"J Thiele","year":"2011","unstructured":"Thiele J, Kvasnicka HM, M\u00fcllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710\u20138.","journal-title":"Blood"},{"key":"3088_CR9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ajh.23554","volume":"88","author":"AB Madelung","year":"2013","unstructured":"Madelung AB, Bondo H, Stamp I, Loevgreen P, Nielsen SL, Falensteen A, et al. World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations\u2014The Danish experience. Am J Hematol. 2013;88:1012\u20136.","journal-title":"Am J Hematol"},{"key":"3088_CR10","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/modpathol.2013.196","volume":"27","author":"U Gianelli","year":"2014","unstructured":"Gianelli U, Bossi A, Cortinovis I, Sabattini E, Tripodo C, Boveri E, et al. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Mod Pathol. 2014;27:814\u201322.","journal-title":"Mod Pathol"},{"key":"3088_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/ajh.24788","volume":"92","author":"G Jeryczynski","year":"2017","unstructured":"Jeryczynski G, Thiele J, Gisslinger B, W\u00f6lfler A, Schalling M, Glei\u00df A, et al. Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017;92:885\u201391.","journal-title":"Am J Hematol"},{"key":"3088_CR12","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","volume":"98","author":"G Barosi","year":"2001","unstructured":"Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M, et al. Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98:3249\u201355.","journal-title":"Blood"},{"key":"3088_CR13","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356\u201363.","journal-title":"J Clin Oncol"},{"key":"3088_CR14","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"3088_CR15","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjh.13343","volume":"170","author":"A Iurlo","year":"2015","unstructured":"Iurlo A, Cattaneo D, Giunta M, Gianelli U, Consonni D, Fraquelli M, et al. Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre. Br J Haematol. 2015;170:890\u20132.","journal-title":"Br J Haematol"},{"key":"3088_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00277-021-04672-z","volume":"101","author":"D Luque Paz","year":"2022","unstructured":"Luque Paz D, Cottin L, Lippert E, Robin J-B, Bescond C, Genevieve F, et al. Different number of circulating CD34\u2009+\u2009cells in essential thrombocythemia, prefibrotic\/early primary myelofibrosis, and overt primary myelofibrosis. Ann Hematol. 2022;101:893\u20136.","journal-title":"Ann Hematol"},{"key":"3088_CR17","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"3088_CR18","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","volume":"29","author":"L Sandrin","year":"2003","unstructured":"Sandrin L, Fourquet B, Hasquenoph J-M, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705\u201313.","journal-title":"Ultrasound Med Biol"},{"key":"3088_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000371","volume":"4","author":"NF \u00d8bro","year":"2020","unstructured":"\u00d8bro NF, Grinfeld J, Belmonte M, Irvine M, Shepherd MS, Rao TN, et al. Longitudinal Cytokine Profiling Identifies GRO-\u03b1 and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia. HemaSphere. 2020;4:e371.","journal-title":"HemaSphere"},{"key":"3088_CR20","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s00277-016-2784-x","volume":"95","author":"C Orvain","year":"2016","unstructured":"Orvain C, Luque Paz D, Dobo I, Cottin L, Le Calvez G, Chauveau A, et al. Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. Ann Hematol. 2016;95:1819\u201323.","journal-title":"Ann Hematol"},{"key":"3088_CR21","first-page":"1123","volume":"88","author":"F Passamonti","year":"2003","unstructured":"Passamonti F, Vanelli L, Malabarba L, Rumi E, Pungolino E, Malcovati L, et al. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica. 2003;88:1123\u20139.","journal-title":"Haematologica"},{"key":"3088_CR22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861\u20139.","journal-title":"Leukemia"},{"key":"3088_CR23","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1182\/blood.2023020270","volume":"143","author":"M Usart","year":"2024","unstructured":"Usart M, Stetka J, Luque Paz D, Hansen N, Kimmerlin Q, Almeida Fonseca T, et al. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-\u03b1 in JAK2 -V617F\u2013positive myeloproliferative neoplasms. Blood. 2024;143:2490\u2013503.","journal-title":"Blood"},{"key":"3088_CR24","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1182\/blood-2018-04-846220","volume":"132","author":"S Jacquelin","year":"2018","unstructured":"Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, et al. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood. 2018;132:2707\u201321.","journal-title":"Blood"},{"key":"3088_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32928-3","volume":"13","author":"MF-U Rahman","year":"2022","unstructured":"Rahman MF-U, Yang Y, Le BT, Dutta A, Posyniak J, Faughnan P, et al. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm. Nat Commun. 2022;13:5347.","journal-title":"Nat Commun"},{"key":"3088_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32927-4","volume":"13","author":"S Rai","year":"2022","unstructured":"Rai S, Grockowiak E, Hansen N, Luque Paz D, Stoll CB, Hao-Shen H, et al. Inhibition of interleukin-1\u03b2 reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nat Commun. 2022;13:5346.","journal-title":"Nat Commun"},{"key":"3088_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/ejh.12332","volume":"93","author":"ME Bj\u00f8rn","year":"2014","unstructured":"Bj\u00f8rn ME, Andersen CL, Jensen MK, Hasselbalch HC. Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. Eur J Haematol. 2014;93:224\u20138.","journal-title":"Eur J Haematol"},{"key":"3088_CR28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood.2024027363","volume":"146","author":"L Varricchio","year":"2025","unstructured":"Varricchio L, Mosoyan G, Elghaity-Beckley S, Mia MdB, Handa S, Salib C, et al. Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression. Blood. 2025;146:1612\u201324.","journal-title":"Blood"},{"key":"3088_CR29","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","volume":"33","author":"DAC Fisher","year":"2019","unstructured":"Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling. Leukemia. 2019;33:1978\u201395.","journal-title":"Leukemia"},{"key":"3088_CR30","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood.2019004095","volume":"136","author":"HFE Gleitz","year":"2020","unstructured":"Gleitz HFE, Dugourd AJF, Leimk\u00fchler NB, Snoeren IAM, Fuchs SNR, Menzel S, et al. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood. 2020;136:2051\u201364.","journal-title":"Blood"},{"key":"3088_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110189","volume":"38","author":"AJ Affandi","year":"2022","unstructured":"Affandi AJ, Carvalheiro T, Ottria A, De Haan JJ, Brans MAD, Brandt MM, et al. CXCL4 drives fibrosis by promoting several key cellular and molecular processes. Cell Rep. 2022;38:110189.","journal-title":"Cell Rep"},{"key":"3088_CR32","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41375-024-02354-z","volume":"38","author":"D Capitanio","year":"2024","unstructured":"Capitanio D, Calledda FR, Abbonante V, Cattaneo D, Moriggi M, Bartalucci N, et al. Proteomic screening identifies PF4\/Cxcl4 as a critical driver of myelofibrosis. Leukemia. 2024;38:1971\u201384.","journal-title":"Leukemia"},{"key":"3088_CR33","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1182\/blood.V97.11.3665","volume":"97","author":"RA Mesa","year":"2001","unstructured":"Mesa RA, Li CY, Schroeder G, Tefferi A. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia. Blood. 2001;97:3665\u20137.","journal-title":"Blood"},{"key":"3088_CR34","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/hep.20935","volume":"42","author":"P Cal\u00e8s","year":"2005","unstructured":"Cal\u00e8s P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet M-C, Konat\u00e9 A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373\u201381.","journal-title":"Hepatology"},{"key":"3088_CR35","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846\u201354.","journal-title":"Hepatology"},{"key":"3088_CR36","doi-asserted-by":"publisher","first-page":"e35631","DOI":"10.1371\/journal.pone.0035631","volume":"7","author":"G Barosi","year":"2012","unstructured":"Barosi G, Rosti V, Bonetti E, Campanelli R, Carolei A, Catarsi P, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS ONE. 2012;7:e35631.","journal-title":"PLoS ONE"},{"key":"3088_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2014.113845","volume":"102","author":"J Grinfeld","year":"2017","unstructured":"Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica. 2017;102:7\u201317.","journal-title":"Haematologica"},{"key":"3088_CR38","first-page":"1","volume":"365","author":"G Coltro","year":"2021","unstructured":"Coltro G, Loscocco GG, Vannucchi AM. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): a continuum of different disease entities. Int Rev Cell Mol Biol. 2021;365:1\u201369.","journal-title":"Int Rev Cell Mol Biol"},{"key":"3088_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0290-9","volume":"10","author":"T Barbui","year":"2020","unstructured":"Barbui T, Thiele J, Ferrari A, Vannucchi AM, Tefferi A. The new WHO classification for essential thrombocythemia calls for revision of available evidences. Blood Cancer J. 2020;10:22.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03088-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03088-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03088-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:28Z","timestamp":1790250208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03088-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3088"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03088-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Clinical and biological information at diagnosis and during follow-up was extracted from the BCB FIMBANK database. This study (NCT03869476) was conducted in accordance with the Declaration of Helskini and was approved by the national authorities (2019-A00375-51). Patients provided their informed consent to be included in the present study (NCT03869476) and in the BCB FIMBANK.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}